Table 2.
Patients rebleeding in the key study populations of repeated hepatic venous pressure gradient (HVPG) measurement in the pharmacological prevention of variceal rebleeding (absolute numbers in parentheses)
| Feu15 | Villanueva16 | McCormick17 | Villanueva4 | Patch6 | |
| Total No of patients | 83 | 43* | 63 | 72† | 51‡ |
| HVPG not measured | 17%(14) | 0% | 11%(7) | 0% | 22%(11) |
| HVPG not remeasured | 17%(14) | 28%(12) | 17%(11)§ | 33%(23) | 65%(33) |
| Rebleeding not remeasured | 64%(9/14) | 17%(2/12) | 28%(5/18)¶ | 17%(4/23) | 33%(11/33) |
| Rebleeding (patient groups) | |||||
| Total | 36%(25/69) | 26%(11/43) | 37%(16/44) | 33%(24/72) | 37%(19/51) |
| Haemodynamic responders | 8%(2/25) | 7%(1/14) | 43%(12/28) | 16%(4/25) | 11%(1/9) |
| Haemodynamic non-responders | 52%(23/44) | 47%(8/17) | 25%(4/16) | 67%(16/24) | 22%(2/9) |
| Repeat HVPG ⩽12 mm Hg | 0%(0/8) | 0%(0/9) | 30%(7/23) | ?(?/7) | 50%(1/2) |
| Rebleeding before remeasurement | 7%(5/69) | Some** | 16%(7/44) | Some** | 22%(5/23) |
*Initial cohort 121 patients, 86 of whom were included (43 for each treatment arm).
†Initial cohort 233 patients, 144 of whom were included (72 for each treatment arm).
‡Initial cohort 205 patients, 102 of whom were included (51 for each treatment arm).
§Only 44 patients included in the study (one patient excluded because of low initial and repeat HVPG (7 mm Hg)).
¶Rebleeding rate in both non-measured and non-remeasured patients (rebleeding occurred in two of seven patients who did not have their baseline HVPG measured and in three of 11 patients who did not have a repeat HVPG measurement).
**Number not stated (in the second study (Villanueva4) it can be derived that this number must be between 1 and 4).